Startups
Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
EU-StartupsEuropean Union · EUROPE
Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Serie...
Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors, including the […]
The post Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases appeared first on EU-Startups.